Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1316 participants.
Also called NCT07307235
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 1,316 participants
- Sponsor
- Registry
-
NCT07307235
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT07307235. Randomized; no masking; primary purpose treatment. Start 2025-12-13 (actual); primary completion 2027-06-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- iGlarLixi (insulin glargine/lixisenatide)
- Intervention (Drug)
- standard of care (basal insulin or premixed insulin, excluding any GLP-1 receptor agonist-containing drugs)
- Lead sponsor
- Shanghai Zhongshan Hospital
- Collaborator
- Sanofi (China) Investment Co., Ltd
Record details
- Record id
cardio:ct-nct07307235- Content hash
8af87215261df9172d58858a40caa69d13bc71638d00735ce98965d57582fbad